Syndetics omslagsbild
Bild från Syndetics

Suzlon Energy / Sidharth Sinha.

Av: Materialtyp: TextSerie: Utgivningsuppgift: London : Indian Institute of Management, Ahmedabad, 2016Beskrivning: 1 online resource : illustrationsInnehållstyp:
  • text
Medietyp:
  • computer
Bärartyp:
  • online resource
ISBN:
  • 9781526429544 (ebook) :
Ämnen: DDK-klassifikation:
  • 657 23
Onlineresurser: In February 2015, Suzlon Energy had signed a binding agreement with Center bridge Partners to sell 100% stake in Senvion, a wholly owned subsidiary of the Suzlon group. The deal was valued at EUR1 billion (approximately Rs.7,200 crore) equity value in an all cash transaction and a future earn out of upto an additional EUR 50 million(approximately Rs.360 crore).The sale of Senvion was the last major step in the implementation of the Corporate Debt Restructuring agreement that Suzlon had concluded with banks and financial institutions. Around the same time of the sale Suzlon received an offer from Dilip Shanghvi Family and Associates, promoters of Sun Pharma, for an equity investment of Rs.1,800 crore through a preferential issue of 100 crore shares at Rs.18 per share. In case Suzlon decided to accept the offer, the shareholding of the new shareholder would be around the same level as that of Mr. Tulsi Tanti, the current controlling shareholder of Suzlon.
Inga fysiska exemplar för denna post

Originally published in Sinha, S. (2016). Suzlon Energy. F&A0533. Ahmedabad: Indian Institute of Management, Ahmedabad.

In February 2015, Suzlon Energy had signed a binding agreement with Center bridge Partners to sell 100% stake in Senvion, a wholly owned subsidiary of the Suzlon group. The deal was valued at EUR1 billion (approximately Rs.7,200 crore) equity value in an all cash transaction and a future earn out of upto an additional EUR 50 million(approximately Rs.360 crore).The sale of Senvion was the last major step in the implementation of the Corporate Debt Restructuring agreement that Suzlon had concluded with banks and financial institutions. Around the same time of the sale Suzlon received an offer from Dilip Shanghvi Family and Associates, promoters of Sun Pharma, for an equity investment of Rs.1,800 crore through a preferential issue of 100 crore shares at Rs.18 per share. In case Suzlon decided to accept the offer, the shareholding of the new shareholder would be around the same level as that of Mr. Tulsi Tanti, the current controlling shareholder of Suzlon.

Description based on XML content.

Licensed e-book